AstraZeneca
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Drug Interaction Study of Saxagliptin in Combination With Dapagliflozin in Healthy Participants
- First Posted Date
- 2012-08-13
- Last Posted Date
- 2015-05-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 42
- Registration Number
- NCT01662999
- Locations
- 🇺🇸
Icon Clinical Pharmacology, Omaha, Nebraska, United States
Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
- Conditions
- Diabetes Type 2
- Interventions
- First Posted Date
- 2012-07-30
- Last Posted Date
- 2015-08-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 365
- Registration Number
- NCT01652729
- Locations
- 🇺🇸
Research Site, Spokane, Washington, United States
🇺🇸Reseach Site, Rapid City, South Dakota, United States
Efficacy and Safety of Exenatide Once Weekly Suspension in Subjects With Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2012-07-30
- Last Posted Date
- 2018-07-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 377
- Registration Number
- NCT01652716
- Locations
- 🇺🇸
Research Site, Spokane, Washington, United States
Assessing a Stool Symptom Screener in Patients With Chronic Opioid-Induced Constipation
- Conditions
- Opioid-induced Constipation
- First Posted Date
- 2012-07-20
- Last Posted Date
- 2014-10-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 79
- Registration Number
- NCT01645371
Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes
- Conditions
- Type 2 Diabetes
- Interventions
- First Posted Date
- 2012-07-20
- Last Posted Date
- 2016-06-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 320
- Registration Number
- NCT01646320
- Locations
- 🇺🇸
Torrance Clinical Research Institute Inc., Lomita, California, United States
🇺🇸Diabetes Medical Center Of California, Northridge, California, United States
🇺🇸Cassidy Medical Group/Clinical Research Advantage, Vista, California, United States
Validation of Questionnaire and Assessment of Patient Satisfaction for Budesonide/Formoterol Fix Combination Dry Powder Inhalers (DPI) in Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- First Posted Date
- 2012-07-20
- Last Posted Date
- 2012-10-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 446
- Registration Number
- NCT01646424
- Locations
- 🇹🇷
Research Site, Yozgat, Turkey
A Study to Assess the Bioequivalence of R406 in Healthy Volunteers When Given 100mg and 150 mg of Fostamatinib
- Conditions
- Healthy Volunteers
- Interventions
- Drug: Mannitol-based 38% drug-loaded tabletDrug: MCC-based 13% drug loaded tablets
- First Posted Date
- 2012-07-20
- Last Posted Date
- 2013-03-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 88
- Registration Number
- NCT01645085
Efficacy and Safety Study to Compare Formoterol Fumerate in the Pressair DPI to the Foradil Aerolizer in Patient With Mild to Moderate Asthma
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2012-07-16
- Last Posted Date
- 2017-02-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 174
- Registration Number
- NCT01641081
- Locations
- 🇺🇸
Forest Investigative Site 1333, Baltimore, Maryland, United States
🇺🇸Forest Investigative Site 909, Phoenix, Arizona, United States
🇺🇸Forest Investigative Site 1347, San Jose, California, United States
A Long Term Study to Assess the Safety of Fostamatinib in Patients in Asia With Rheumatoid Arthritis
- First Posted Date
- 2012-07-13
- Last Posted Date
- 2014-03-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 115
- Registration Number
- NCT01640054
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of Inhaled AZD7594
- Conditions
- SafetyPharmacokineticsPharmacodynamics of AZD7594
- Interventions
- Drug: Placebo to match
- First Posted Date
- 2012-07-10
- Last Posted Date
- 2013-06-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 73
- Registration Number
- NCT01636024
- Locations
- 🇬🇧
Research Site, London, UK, United Kingdom